



(51) International Patent Classification:

A61K 47/48 (2006.01) *A61K 31/465* (2006.01)
A61P 25/30 (2006.01) *C07D 213/82* (2006.01)

(21) International Application Number:

PCT/IB2011/052446

(22) International Filing Date:

3 June 2011 (03.06.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/351,342 4 June 2010 (04.06.2010) US

(71) **Applicant** (for all designated States except US): **PFIZER VACCINES LLC** [US/US]; 235 East 42nd Street, New York, NY 10017 (US).

(72) Inventors; and

(75) **Inventors/Applicants** (for US only): **ANASTASIOU, Nickolas** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **BHATTACHARYA, Keshab** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **BROWN, Alan, Daniel** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **DAVIS, Heather, Lynn** [CA/CA]; Pfizer Vaccines Research, Ottawa Laboratories, 340 Terry Fox Drive, Suite 200, Ottawa, Ontario K2K 3A2 (CA). **FINNEMAN, Jari, Ilmari** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **GERVAIS, David, P.** [GB/GB]; Jarcens, Gomeldon, Salisbury, Wiltshire SP4 6JZ (GB). **JONES, Lyn, Howard** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **KOLHE, Parag, Ashok** [IN/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **MCCLUSKIE, Michael, John** [CA/CA]; Pfizer Vaccines Research Ottawa Laboratories, 340 Terry Fox

Drive, Suite 200, Ottawa, Ontario K2K 3A2 (CA). **MEHELIC, Paul, Robert** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **MERSON, James, Richard** [GB/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121 (US). **PARSONS, Erin, Kristen** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US). **PRYDE, David, Cameron** [GB/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). **STEAD, David, Robert** [GB/US]; Pfizer Global Research and Development, 10777 Science Center Drive, San Diego, CA 92121 (US). **THORN, Jennifer, Marie** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017 (US).


(74) **Agents**: **BENSON, Gregg, C.** et al.; Pfizer Inc., Eastern Point Road, MS 9114, Groton, CT 06340 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) **Title**: CONJUGATES FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION



(57) **Abstract**: The present invention relates in part to nicotine-derived hapten-carrier conjugates of the formula (III): wherein m, n, W, -(spacer)-, X* and Y are as defined in the description. In certain embodiments, said nicotine-derived hapten-carrier conjugates can be used to prepare vaccines for the treatment and/or prevention of nicotine addiction.

**Declarations under Rule 4.17:**

— as to the identity of the inventor (Rule 4.17(i))

Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

— with sequence listing part of description (Rule 5.2(a))